https://www.thebodypro.com/author/aid-sinfo

Latest by AIDSinfo

Promo Image
News

Call for Nominations for New Scientific/Clinical Members for the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents

The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is accepting nominations for new scientific/clinical members with expertise in HIV medicine. The Panel is seeking candidates w...

DHHS Adult and Adolescent Antiretroviral Treatment Guidelines Panel Releases Supplemental Information Regarding the Role of Rilpivirine as Initial Therapy Img

DHHS Adult and Adolescent Antiretroviral Treatment Guidelines Panel Releases Supplemental Information Regarding the Role of Rilpivirine as Initial Therapy

Following last week's approval of the all-in-one pill Complera (which consists of Edurant, Viread and Emtriva), the FDA's HIV treatment guidelines panel has announced that Edurant (a.k.a. rilpivirine) is now an "alternative" first-line medication. Th...

Promo Image

Recommended Immunizations for HIV-Positive Adults

Immunization NameAssociated DiseaseDosageComments and WarningsRecommended for All HIV-Positive AdultsHepatitis B virus (HBV)Hepatitis B3 shots over a 6-month periodRecommended unless there is evidence of immunity or active hepatitis. Blood test to ch...

Promo Image

Entecavir in Hepatitis B Virus (HBV)/HIV Co-Infected Patients

Previously, the guidelines recommended entecavir as an option for patients who required treatment for Hepatitis B virus (HBV) but not HIV infection. This recommendation was based on in vitro data showing no significant activity of entecavir against H...

Promo Image

Update on the New York City "Superbug"

In 2004, a New York City man was infected with HIV and went on to develop AIDS in a remarkably short time period -- less than 20 months from the time of infection, whereas progression from infection with HIV to AIDS generally occurs over a period of ...

Promo Image

FDA Approves Generic Formulation of Didanosine (ddI) Delayed Release Capsules

The Food and Drug Administration (FDA) today (December 3, 2004) approved a generic formulation of Didanosine (ddI) Delayed Release capsules, 200 mg, 250 mg, and 400 mg for use in combination with other antiretroviral agents in the treatment of HIV-1 ...